Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Financial giants have made a conspicuous bearish move on ResMed. Our analysis of options history for ResMed (NYSE:RMD) revealed 10 unusual trades.
Delving into the details, we found 20% of traders were bullish, while 40% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $110,805, and 8 were calls, valued at $345,662.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $230.0 for ResMed over the last 3 months.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for ResMed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across ResMed's significant trades, within a strike price range of $170.0 to $230.0, over the past month.
Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
---|---|---|---|---|---|---|---|---|---|---|---|
RMD | CALL | SWEEP | NEUTRAL | 08/16/24 | $12.3 | $11.7 | $12.11 | $210.00 | $84.5K | 661 | 193 |
RMD | PUT | SWEEP | BEARISH | 09/20/24 | $15.3 | $14.8 | $14.8 | $210.00 | $74.0K | 34 | 64 |
RMD | CALL | SWEEP | BULLISH | 09/20/24 | $7.1 | $7.1 | $7.1 | $230.00 | $50.4K | 101 | 71 |
RMD | CALL | SWEEP | NEUTRAL | 10/18/24 | $45.8 | $44.1 | $44.95 | $170.00 | $44.9K | 7 | 15 |
RMD | CALL | SWEEP | NEUTRAL | 08/16/24 | $12.3 | $11.5 | $11.9 | $210.00 | $38.0K | 661 | 63 |
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
In light of the recent options history for ResMed, it's now appropriate to focus on the company itself. We aim to explore its current performance.
1 market experts have recently issued ratings for this stock, with a consensus target price of $204.0.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ResMed with Benzinga Pro for real-time alerts.
Posted In: RMD